Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01783574 · ClinicalTrials.gov registry record · NA

Testosterone Antidepressant Augmentation in Women

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
101
Enrollment target

NCT01783574: Completed NA study, sponsored by Massachusetts General Hospital.

NCT01783574 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01783574, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
101 participants
Enrollment target

Study Summary

The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive symptoms in women with Major Depressive Disorder (MDD) and antidepressant partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation improves fatigue and sexual dysfunction.

Interventions

  • DRUG Placebo
  • DRUG Testosterone

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2013-08
Est. Completion 2017-01-27
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01783574

The ClinicalTrials.gov registry entry for NCT01783574 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01783574 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01783574 about?

NCT01783574 is a clinical study titled "Testosterone Antidepressant Augmentation in Women". The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive symptoms in women with Major Depressive Disorder (MDD) and antidepressant partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women with MDD and antidepressant partial/nonrespons...

What is the current status of trial NCT01783574?

This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2013-08. Estimated completion is 2017-01-27.

What interventions are being tested in trial NCT01783574?

The interventions under investigation include: Placebo (DRUG), Testosterone (DRUG).

Who is sponsoring clinical trial NCT01783574?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.